Clinic
Integrated Pain Solutions PLLC
Integrated Pain Solutions PLLC was paid $12.66M by Medicaid between Jan 2018 and Dec 2024, across 54 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 53% of everything it billed.
33Billing provider infoINTEGRATED PAIN SOLUTIONS PLLC
SOUTHERN PINES, NC 28387
SOUTHERN PINES, NC 28387
33aNPI1790728921assigned 06/14/2006
33bProvider typePain Clinic/Center
28Total paid$12.66M
24GClaims328,846
24DCodes billed54
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Clinic/Center providers in North Carolina
Rank by total paid#1 of 9
Median peer was paid$251K
This provider vs. median51×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,689 | $1.65M | |
| 2019 | 53,036 | $1.91M | |
| 2020 | 44,441 | $1.80M | |
| 2021 | 47,522 | $1.86M | |
| 2022 | 49,743 | $1.94M | |
| 2023 | 42,621 | $1.87M | |
| 2024incomplete | 35,794 | $1.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 53% | 155,920 | 118,331 | $6.68M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23% | 46,952 | 38,780 | $2.93M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 17% | 35,299 | 28,632 | $2.18M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.6% | 2,683 | 2,103 | $332K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 2,810 | 2,387 | $224K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 4,736 | 3,552 | $137K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 709 | 680 | $74K |
| 64483 | <1% | 387 | 218 | $28K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 446 | 392 | $21K |
| 96127 | <1% | 4,687 | 3,564 | $17K | |
| 62323 | <1% | 238 | 199 | $16K | |
| 27096 | <1% | 160 | 108 | $7K |
42 more codes
| 99406 | <1% | 601 | $3K | |
| 77002 | <1% | 92 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 768 | $2K |
| 99490 | Ccm add 20min | <1% | 144 | $1K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 1,868 | $1K |
| 20610 | <1% | 27 | $937.90 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 149 | $733.86 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 29 | $530.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 698 | $253.67 |
| 99439 | <1% | 38 | $216.44 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,461 | $214.61 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 14 | $34.16 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 12,551 | $0.22 |
| 1036F | <1% | 320 | $0.12 | |
| 1101F | <1% | 2,225 | $0.05 | |
| G8734 | Elder maltreatment screen documented as negative, follow-up is not required | <1% | 193 | $0.03 |
| 1006F | <1% | 1,796 | $0.02 | |
| 1124F | <1% | 681 | $0.02 | |
| G9717 | Documentation stating the patient has had a diagnosis of bipolar disorder | <1% | 22 | $0.01 |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 2,505 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 2,229 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 1,154 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 6,275 | $0.00 |
| 1123F | 0% | 805 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 496 | $0.00 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 273 | $0.00 |
| G8542 | Functional outcome assessment using a standardized tool is documented; no functional deficiencies identified, care plan not required | 0% | 891 | $0.00 |
| G8433 | Screening for depression not completed, documented patient or medical reason | 0% | 41 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 8,063 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 1,426 | $0.00 |
| G8482 | Influenza immunization administered or previously received | 0% | 1,100 | $0.00 |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 4,576 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 18,447 | $0.00 |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 1,265 | $0.00 |
| G8942 | Functional outcome assessment using a standardized tool is documented within the previous 30 days and a care plan, based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 22 | $0.00 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 121 | $0.00 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | 0% | 62 | $0.00 |
| 4004F | 0% | 143 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 33 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 191 | $0.00 |
| 1100F | 0% | 12 | $0.00 | |
| 3288F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTORRES, LOUIS (SOLE MEMBER)